Stock listing

NASDAQ:TLSA Tiziana Life Sciences Ltd Stock

Home listing (NASDAQ) of Tiziana Life Sciences Ltd

Follow Tiziana Life Sciences Ltd into a list and get an email when it puts out news.

Share price · NASDAQ:TLSA

$0.621 USD -0.059 (-8.7%)

Close on Nov 20, 2026

Past year -61.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.612 – $0.700 USDNov 20, 2026
Volume
231,243 sharesNov 20, 2026
Market cap
$78.98M USDAt the close on Nov 20, 2026 · price × 127.3M shares outstanding
52-week range
$0.550 – $1.900 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$586,725 USDMedian day 490,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tiziana Life Sciences Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TLSA · Home$0.621 USD-0.059 (-8.7%)231,243$0.690$0.700$0.612$0.680Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TLSA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.621-0.059-8.7%$0.690$0.700$0.612231,243
$0.680-0.130-16.0%$0.790$0.800$0.680339,100
$0.810+0.160+24.6%$0.670$0.840$0.6501,280,900
$0.650+0.070+12.1%$0.580$0.750$0.580740,000
$0.580+0.010+1.8%$0.570$0.610$0.550665,300
$0.570-0.040-6.6%$0.600$0.630$0.570266,500
$0.610-0.010-1.6%$0.630$0.650$0.610194,200
$0.620+0.010+1.6%$0.640$0.660$0.610359,600
$0.610-0.060-9.0%$0.680$0.680$0.610395,100
$0.670-0.020-2.9%$0.700$0.700$0.660305,500
$0.690+0.070+11.3%$0.620$0.700$0.620324,500
$0.620-0.020-3.1%$0.660$0.660$0.570766,200
$0.640-0.050-7.2%$0.700$0.710$0.620420,900
$0.690+0.020+3.0%$0.660$0.730$0.650539,500
$0.670-0.130-16.3%$0.840$0.860$0.6202,849,700
$0.800-0.100-11.1%$0.900$0.920$0.7901,292,100
$0.900-0.050-5.3%$0.950$0.950$0.900187,600
$0.950+0.080+9.2%$0.890$0.960$0.880250,700
$0.870-0.010-1.1%$0.880$0.940$0.870189,400
$0.880-0.070-7.4%$0.950$0.950$0.860377,700
$0.950-0.050-5.0%$0.970$0.980$0.930252,000
$1.000-0.010-1.0%$0.980$1.010$0.940494,000
$1.0100.0000.0%$1.030$1.030$0.970421,500
$1.0100.0000.0%$1.020$1.030$0.990299,200
$1.010-0.040-3.8%$1.060$1.070$0.990332,500
$1.0500.0000.0%$1.080$1.100$1.030558,800
$1.0500.0000.0%$1.050$1.070$1.020264,400
$1.050-0.040-3.7%$1.060$1.080$1.030581,400
$1.0900.0000.0%$1.090$1.120$1.050492,600
$1.090-0.100-8.4%$1.200$1.200$1.070567,600
$1.190+0.060+5.3%$1.140$1.250$1.1302,423,400
$1.130+0.030+2.7%$1.110$1.150$1.110449,900
$1.100-0.010-0.9%$1.110$1.140$1.070384,600
$1.110+0.040+3.7%$1.080$1.140$1.050628,200
$1.070-0.050-4.5%$1.120$1.140$1.070274,400
$1.120-0.020-1.8%$1.160$1.200$1.100436,800
$1.140+0.030+2.7%$1.110$1.190$1.090697,700
$1.110+0.160+16.8%$1.000$1.140$0.9701,518,700
$0.950-0.030-3.1%$0.980$1.030$0.940511,300
$0.980-0.030-3.0%$1.010$1.050$0.960389,000
$1.010-0.030-2.9%$1.030$1.080$1.000382,700
$1.040-0.010-1.0%$1.100$1.110$1.000706,600
$1.050+0.160+18.0%$0.890$1.060$0.8901,573,700
$0.890-0.010-1.1%$0.890$0.890$0.870623,900
$0.900-0.010-1.1%$0.940$0.950$0.900534,300
$0.910-0.060-6.2%$0.970$0.980$0.910414,800
$0.970+0.200+26.0%$0.850$1.010$0.8501,743,200
$0.770-0.080-9.4%$0.850$0.880$0.760844,100
$0.850-0.040-4.5%$0.890$0.890$0.810659,200
$0.890-0.070-7.3%$0.960$0.980$0.880564,200
$0.9600.0000.0%$0.980$1.000$0.930272,900
$0.960-0.020-2.0%$0.960$0.980$0.950194,600
$0.980-0.010-1.0%$0.990$1.010$0.950245,500
$0.990-0.030-2.9%$1.020$1.030$0.960908,200
$1.020+0.050+5.2%$0.970$1.060$0.950573,900
$0.970+0.040+4.3%$1.050$1.050$0.950517,900
$0.930-0.030-3.1%$0.960$1.000$0.910487,800
$0.960-0.030-3.0%$0.990$1.000$0.910515,100
$0.990-0.020-2.0%$1.020$1.050$0.970429,700
$1.010-0.070-6.5%$1.100$1.100$1.000565,500
$1.080-0.010-0.9%$1.090$1.140$1.050272,300
$1.090-0.020-1.8%$1.120$1.130$1.080402,600
$1.110-0.040-3.5%$1.180$1.180$1.100441,000
$1.150+0.010+0.9%$1.140$1.250$1.140959,000
$1.140+0.020+1.8%$1.120$1.170$1.090832,300
$1.120+0.050+4.7%$1.080$1.160$1.0401,573,000

Splits

2 splits since 2019 · NASDAQ:TLSA · every price before a split is adjusted for it

DayRatioWhat
2.499-for-1Split
2-for-1Split
Ticker
NASDAQ:TLSA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tiziana Life Sciences Ltd news

Tiziana Life Sciences Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
42 in the last 12 months · 202 in all · newest Nov 12, 2026 · oldest 2020
Decks
17 decks · latest Nov 9, 2026

Where Tiziana Life Sciences Ltd is listed

ListingExchangeCountryCurrency
NASDAQ:TLSA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TLSABOATSUnited StatesUSD
Lang & Schwarz:A3C5SSLang & SchwarzGermanyEUR
LS Exchange:A3C5SSLS ExchangeGermanyEUR
gettex:0RPgettexGermanyEUR
Frankfurt:0RPFrankfurtGermanyEUR
Dusseldorf:0RPDusseldorfGermanyEUR
Munich:0RPMunichGermanyEUR
Stuttgart:0RPStuttgartGermanyEUR
Tradegate:0RPTradegateGermanyEUR

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$76.73M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.23

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tiziana Life Sciences Ltd · NASDAQ:TLSAUS$78.98MUS$76.73Mn/an/an/an/an/an/a1.23
3D Medicines, Inc. · HKEX:1244US$81.88MUS$48.45Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Kintor Pharmaceutical Ltd · HKEX:9939US$81.70MUS$96.94Mn/a19.8×n/a5.0×−612.3%1.2×n/a
Nkarta, Inc. · NASDAQ:NKTXUS$81.38M−US$75.22Mn/an/an/a0.4×n/a0.0×1.67
Captor Therapeutics SA · GPW:CTXUS$81.11MUS$64.15Mn/a130×n/a5.1×n/a0.0×n/a
Vaxart, Inc. · OTC:VXRTUS$79.89MUS$14.34M2.8×0.1×0.4×1.2×16.0%0.0×1.21
Sensorion SAS · EURONEXT:ALSENUS$79.63M−US$13.98Mn/an/an/a0.9×n/a0.0×n/a
Adocia SA · EURONEXT:ADOCUS$79.30MUS$77.84Mn/a48.1×n/an/an/an/an/a
Nyrada, Inc. · ASX:NYRUS$78.76MUS$73.21Mn/an/an/a12.5×n/a0.0×n/a
TiumBio Co., Ltd. · KRX:321550US$77.24MUS$60.57Mn/a5.4×n/a2.9×−114.1%0.3×n/a
HLB Therapeutics Co., Ltd. · KRX:115450US$76.82MUS$66.93Mn/a1.4×n/a0.7×−28.0%0.0×n/a
Median of the othersUS$79.76MUS$62.36M2.8×5.4×0.4×1.2×−49.9%0.0×1.44

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
7.87 USD · Analysts' mean
EPS, year to Dec 2026
-0.13 · 2 analysts

Team and board

Officers

OfficerRole
Ivor ElrifiChief Executive Officer & Executive Director
Keeren ShahChief Operating Officer & Chief Financial Officer
Paul SpencerBusiness Development, and Investor Relations
Gabriele CerroneExecutive Chairman
Richard KimChief Medical Officer
William TenteChief Regulatory Officer

Board

DirectorRole
Gabriele CerroneExecutive Chairman
Ivor ElrifiChief Executive Officer & Executive Director
John BrancaccioNon-Executive Director
Willy SimonNon-Executive Director

Events

QuarterResultsShare move
Q3 2025Oct 3, 2025−1.5%
Q1 2025Jun 23, 2025 · After close+1.9%
Q3 2024Oct 18, 2024−4.4%
Q3 2022Dec 27, 2022 · After close+1.8%
Q1 2022May 22, 2022 · After close−17.4%
Quarter to Sep 30, 2021Dec 1, 2021−7.9%
Quarter to Jun 30, 2021Sep 24, 2021 · After close+4.0%
Quarter to Mar 31, 2021May 17, 2021 · After close−1.8%
Quarter to Dec 31, 2020Mar 31, 2021−2.5%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical20 slidesNov 9, 2026
Investor Presentation (May 2026)Investor deck18 slidesMay 2026
Investor Presentation (2026)Investor deck19 slides2026
IPO Roadshow (December 2025)IPO roadshow21 slidesDec 12, 2025
Investor Presentation (December 2025)Investor deck18 slidesDecember 2025
Investor Presentation (September 2025)Investor deck18 slidesSeptember 2025
Investor Presentation (July 2025)Investor deck16 slidesJuly 2025
Investor Presentation (March 2025)Investor deck20 slidesMarch 2025
Investor Presentation (August 2024)Investor deck24 slidesAugust 2024
Investor Presentation (May 2024)Investor deck24 slidesMay 2024
All 17 decks
DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck25 slidesOctober 2023
Investor Presentation (September 2023)Investor deck24 slidesSeptember 2023
Investor Presentation (March 2023)Investor deck20 slidesMarch 2023
Investor Presentation (October 2022)Investor deck28 slidesOct 25, 2022
Investor Presentation (August 2020)Investor deck27 slidesAugust 2020
IPO Roadshow (August 2019)IPO roadshow30 slidesAug 6, 2019
IPO Roadshow (September 2018)IPO roadshow36 slidesSep 25, 2018

Open Decks

Financings

RaiseDate
Registered direct offering of ordinary shares
Closed: US$8.8M raised · US$1.25 a share · 1 warrant at US$1.5
Buyers: Ivor Elrifi (2,400,000 ordinary shares, bringing his total holding to 2,757,848 ordinary shares); Gabriele Cerrone (through Panetta Partners Ltd) (1,600,000 ordinary shares, bringing his total holdings to 44,974,830 ordinary shares)
Insiders: Led by CEO Ivor Elrifi, who bought 2,400,000 shares; Executive Chairman Gabriele Cerrone bought 1,600,000 shares through Panetta Partners Ltd
Use of proceeds: Complete Phase 2 na-SPMS and MSA clinical trials and achieve top line data readouts in both
Jan 16, 2026
Public offering of common shares
Cancelled: public offering
Dec 15, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$9.90 an ADS on Nov 20, 2018.

Price
US$9.90 an ADS
ADSs offered
442,910 American depositary shares
Offering size
US$4.4 million
Underwriters' option
Up to 66,437 more ADSs
Listing
TLSA on the Nasdaq Global Market
Underwriter
Laidlaw & Company (UK) Ltd.
ADSs delivered
On or about Nov 23, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceNov 30, 2017
Filed publiclyJul 26, 2018
Amended 6 timesNewest Nov 14, 2018
Shares registered with an exchangeOct 30, 2018
Declared effective by the SECNov 19, 2018
Final prospectus, with the priceNov 21, 2018

Filings

FilingFiled
424B4 · ProspectusNov 21, 2018
EFFECT · Notice that a registration is effectiveNov 19, 2018
CORRESP · Letter to the SECNov 19, 2018
CORRESP · Letter to the SECNov 19, 2018
POS AM · Amendment to an effective registrationNov 14, 2018
EFFECT · Notice that a registration is effectiveNov 9, 2018
CORRESP · Letter to the SECNov 9, 2018
CORRESP · Letter to the SECNov 9, 2018
CORRESP · Letter to the SECNov 7, 2018
CORRESP · Letter to the SECNov 7, 2018
All 56 filings
FilingFiled
CORRESP · Letter to the SECNov 7, 2018
CORRESP · Letter to the SECNov 7, 2018
CORRESP · Letter to the SECNov 5, 2018
CORRESP · Letter to the SECNov 5, 2018
CORRESP · Letter to the SECNov 2, 2018
CORRESP · Letter to the SECNov 2, 2018
CERT · Exchange's certificate of listingNov 1, 2018
CORRESP · Letter to the SECOct 30, 2018
CORRESP · Letter to the SECOct 30, 2018
8-A12B · Registration of shares for listing on an exchangeOct 30, 2018
F-1/A · Registration statement, amendedOct 30, 2018
UPLOAD · Letter from the SECOct 23, 2018
CORRESP · Letter to the SECOct 23, 2018
F-1/A · Registration statement, amendedOct 23, 2018
CORRESP · Letter to the SECOct 18, 2018
F-1/A · Registration statement, amendedOct 18, 2018
UPLOAD · Letter from the SECOct 4, 2018
FWP · Free writing prospectusSep 25, 2018
F-1/A · Registration statement, amendedSep 25, 2018
CORRESP · Letter to the SECSep 24, 2018
UPLOAD · Letter from the SECSep 24, 2018
CORRESP · Letter to the SECAug 31, 2018
F-1/A · Registration statement, amendedAug 23, 2018
UPLOAD · Letter from the SECAug 16, 2018
F-1 · Registration statementJul 26, 2018
UPLOAD · Letter from the SECMay 24, 2018
DRSLTR · Letter to the SEC with a draftMay 10, 2018
DRS/A · Draft registration statement, amendedMay 10, 2018
UPLOAD · Letter from the SECMar 13, 2018
DRS/A · Draft registration statement, amendedFeb 27, 2018
DRS/A · Draft registration statement, amendedFeb 27, 2018
DRS/A · Draft registration statement, amendedFeb 27, 2018
DRS · Draft registration statementFeb 27, 2018
DRSLTR · Letter to the SEC with a draftFeb 26, 2018
DRSLTR · Letter to the SEC with a draftFeb 26, 2018
UPLOAD · Letter from the SECFeb 22, 2018
DRS/A · Draft registration statement, amendedFeb 9, 2018
DRS · Draft registration statementFeb 9, 2018
DRS/A · Draft registration statement, amendedFeb 8, 2018
DRSLTR · Letter to the SEC with a draftFeb 8, 2018
DRS · Draft registration statementFeb 8, 2018
UPLOAD · Letter from the SECJan 22, 2018
DRS/A · Draft registration statement, amendedDec 22, 2017
DRS · Draft registration statementDec 22, 2017
UPLOAD · Letter from the SECDec 6, 2017
DRS · Draft registration statementNov 30, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue234.0K14.6M141.0K89.8K250.0K16.0K10.7K8.79K
Gross profit-234.0K-14.6M-141.0K-89.8K-250.0K-16.0K-10.7K-8.79K
Research and development10.3M5.23M8.11M13.0M13.2M5.99M3.71M5.51M6.01M4.01M
Selling, general and administrative10.9M10.6M9.87M1.63M1.15M18.0M6.21M4.42M72.0M33.6M
Operating income-21.1M-15.8M-18.0M-14.6M-27.4M-28.0M-9.92M-9.87M-10.5M-9.88M
Depreciation and amortization234.0K12.0K7.00K1.00K8.00K5.00K5.00K16.0K13.0K11.0K
EBITDA-20.9M-15.8M-18.0M-14.6M-27.4M-28.0M-9.92M-9.85M-10.5M-9.87M
Interest expense18.0K1.77M412.0K876.0K237.4K435.3K92.0K12.0K12.0K12.0K
Income before tax-18.4M-16.7M-17.2M-15.4M-26.7M-28.3M-10.0M-9.88M-10.5M-9.89M
Income tax-4.88M449.0K811.0K-3.24M-2.21M-2.21M-1.95M-1.91M-121.0K
Net income-18.4M-11.9M-17.7M-15.4M-23.4M-26.1M-9.32M-7.93M-8.59M-9.77M
Earnings per share, basic-0.16-0.11-0.17-0.15-0.24-0.16-0.07-0.06-8.59-11.35
Earnings per share, diluted-0.11-0.17-0.15-0.24-0.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.01M3.72M1.18M18.1M42.2M65.8M200.0K5.30M64.0K5.80M
Short-term investments01000000.0T1000000.0T
Receivables4.26M3.69M6.05M5.86M5.27M3.78M1.29M1.29M1.55M93.6K
Inventory-5.99M-5.31M-2.28K-1.29M000
Current assets8.55M7.51M7.34M24.3M48.7M70.2M1.50M6.91M2.45M5.02M
Property, plant and equipment16.0K10.0K17.0K17.0K3.00K6.00K7.00K23.0K28.0K
Goodwill-35.6K000
Total assets11.5M11.3M12.2M26.5M48.8M70.7M2.38M6.92M2.47M5.05M
Accounts payable7.17M7.23M6.39M6.53M6.18M5.59M6.40M5.95M4.42M2.14M
Current liabilities11.2M7.35M6.54M6.66M7.55M7.98M7.35M6.40M4.75M1.74M
Long-term debt000
Total debt456.0K106.0K247.0K365.0K1.35M324.0K313.0K302.0K290.0K278.0K
Total liabilities11.4M7.35M6.65M6.91M7.55M8.27M7.89M6.40M4.75M1.74M
Shareholders' equity52.0K3.94M5.54M19.6M41.3M62.4M69.6M75.8M-2.28M4.09M
Shares outstanding118.3M106.7M102.5M101.5M97.9M97.3M136.5M136.5M117.0M106.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-12.8M-1.53M-15.7M-19.6M-21.8M-11.3M-6.80M-4.60M-7.53M-5.62M
Capital spending-21.0K-19.0K00-22.0K-3.00K-4.00K-1-1.00K-48.0K
Free cash flow-12.9M-1.54M-12.4M-16.0M-21.8M-11.3M-6.80M-4.60M-7.53M-5.65M
Cash from investing3.04M-71.0K-1.25M-4.00M130.0K-123.0K-4.00K-788-1.00K-342.0K
Cash from financing10.0M4.50M40.0K-55.0K-23.0K75.3M1.68M10.1M1.54M1.57M
Dividends paid000
Share buybacks1.47M8.57M1.20M453.0K
Change in cash286.0K2.91M-16.9M-23.7M-21.7M63.9M-5.12M5.49M-5.99M-5.69M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
6-K · Report of a foreign issuerNov 5, 2026Current reportSEC
6-K/A · Report of a foreign issuer, amendedNov 2, 2026Current reportSEC
6-K · Report of a foreign issuerNov 2, 2026Current reportSEC
6-K · Report of a foreign issuerOct 21, 2026Current reportSEC
6-K · Report of a foreign issuerOct 16, 2026Current reportSEC
6-K · Report of a foreign issuerOct 16, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
6-K · Report of a foreign issuerSep 28, 2026Current reportSEC
6-K · Report of a foreign issuerSep 21, 2026Current reportSEC
6-K · Report of a foreign issuerSep 17, 2026Current reportSEC
6-K · Report of a foreign issuerAug 24, 2026Current reportSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 4, 2026Current reportSEC
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 15, 2026Current reportSEC
6-K · Report of a foreign issuerMay 28, 2026Current reportSEC
3 · Initial statement of ownershipMay 22, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 21, 2026Current reportSEC
6-K · Report of a foreign issuerMay 19, 2026Current reportSEC
6-K · Report of a foreign issuerMay 14, 2026Current reportSEC
20-F · Annual reportMay 1, 2026Annual reportSEC
NT 20-FApr 30, 2026Explanation requestSEC
6-K · Report of a foreign issuerApr 16, 2026Current reportSEC
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
6-K · Report of a foreign issuerApr 1, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerFeb 25, 2026Current reportSEC
S-8 · Registration statement for employee plansFeb 20, 2026Offer documentSEC
424B5 · ProspectusJan 21, 2026Offer documentSEC
AWJan 21, 2026Other filingsSEC
POS AM · Amendment to an effective registrationJan 20, 2026Offer documentSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
6-K · Report of a foreign issuerJan 16, 2026Current reportSEC
424B5 · ProspectusJan 16, 2026Offer documentSEC
6-K · Report of a foreign issuerJan 16, 2026Current reportSEC
6-K · Report of a foreign issuerJan 9, 2026Current reportSEC
6-K · Report of a foreign issuerDec 29, 2025Current reportSEC
6-K · Report of a foreign issuerDec 19, 2025Current reportSEC
6-K · Report of a foreign issuerDec 17, 2025Current reportSEC
6-K · Report of a foreign issuerDec 17, 2025Current reportSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
424B5 · ProspectusDec 12, 2025Offer documentSEC
FWP · Free writing prospectusDec 12, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 12, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
6-K · Report of a foreign issuerNov 25, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 13, 2025Current reportSEC
6-K · Report of a foreign issuerOct 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerOct 3, 2025Current reportSEC
6-K · Report of a foreign issuerSep 30, 2025Current reportSEC
6-K · Report of a foreign issuerSep 25, 2025Current reportSEC
6-K · Report of a foreign issuerSep 24, 2025Current reportSEC
6-K · Report of a foreign issuerSep 15, 2025Current reportSEC
6-K · Report of a foreign issuerSep 9, 2025Current reportSEC
6-K · Report of a foreign issuerSep 9, 2025Current reportSEC
6-K · Report of a foreign issuerSep 5, 2025Current reportSEC
6-K · Report of a foreign issuerAug 14, 2025Current reportSEC
6-K · Report of a foreign issuerAug 11, 2025Current reportSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
6-K · Report of a foreign issuerJun 13, 2025Current reportSEC
6-K · Report of a foreign issuerJun 13, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 12, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMay 23, 2025Current reportSEC
6-K · Report of a foreign issuerMay 15, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 9, 2025Current reportSEC
20-F/A · Annual report, amendedMay 8, 2025Annual reportSEC
20-F · Annual reportMay 6, 2025Annual reportSEC
6-K · Report of a foreign issuerMay 6, 2025Current reportSEC
NT 20-FApr 30, 2025Explanation requestSEC
6-K · Report of a foreign issuerApr 23, 2025Current reportSEC
6-K · Report of a foreign issuerApr 2, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMar 28, 2025Other filingsSEC
CORRESP · Letter to the SECMar 27, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 27, 2025Other filingsSEC
6-K · Report of a foreign issuerMar 25, 2025Current reportSEC
F-3 · Registration statementMar 24, 2025Offer documentSEC
6-K · Report of a foreign issuerMar 17, 2025Current reportSEC
6-K · Report of a foreign issuerMar 14, 2025Current reportSEC
6-K · Report of a foreign issuerMar 4, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 21, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 11, 2025Current reportSEC
6-K · Report of a foreign issuerJan 31, 2025Current reportSEC
6-K · Report of a foreign issuerJan 24, 2025Current reportSEC
6-K · Report of a foreign issuerJan 22, 2025Current reportSEC
6-K · Report of a foreign issuerJan 10, 2025Current reportSEC
6-K · Report of a foreign issuerJan 8, 2025Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
6-K · Report of a foreign issuerDec 4, 2024Current reportSEC
6-K · Report of a foreign issuerNov 19, 2024Current reportSEC
6-K · Report of a foreign issuerNov 1, 2024Current reportSEC
424B5 · ProspectusNov 1, 2024Offer documentSEC
6-K · Report of a foreign issuerOct 31, 2024Current reportSEC
6-K · Report of a foreign issuerOct 30, 2024Current reportSEC
6-K · Report of a foreign issuerOct 25, 2024Current reportSEC
424B5 · ProspectusOct 25, 2024Offer documentSEC
6-K · Report of a foreign issuerOct 18, 2024Current reportSEC
6-K · Report of a foreign issuerSep 19, 2024Current reportSEC
6-K · Report of a foreign issuerAug 19, 2024Current reportSEC
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
6-K · Report of a foreign issuerAug 1, 2024Current reportSEC
6-K · Report of a foreign issuerJul 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
6-K · Report of a foreign issuerJun 26, 2024Current reportSEC
6-K · Report of a foreign issuerJun 11, 2024Current reportSEC
6-K · Report of a foreign issuerJun 6, 2024Current reportSEC
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
6-K · Report of a foreign issuerMay 30, 2024Current reportSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
20-F · Annual reportMay 10, 2024Annual reportSEC
NT 20-FApr 30, 2024Explanation requestSEC
6-K · Report of a foreign issuerApr 25, 2024Current reportSEC
6-K · Report of a foreign issuerApr 23, 2024Current reportSEC
6-K · Report of a foreign issuerApr 22, 2024Current reportSEC
6-K · Report of a foreign issuerApr 19, 2024Current reportSEC
6-K · Report of a foreign issuerApr 18, 2024Current reportSEC
6-K · Report of a foreign issuerApr 11, 2024Current reportSEC
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
6-K · Report of a foreign issuerJan 8, 2024Current reportSEC
6-K · Report of a foreign issuerJan 5, 2024Current reportSEC
6-K · Report of a foreign issuerJan 5, 2024Current reportSEC
6-K · Report of a foreign issuerDec 29, 2023Current reportSEC
6-K · Report of a foreign issuerDec 19, 2023Current reportSEC
6-K · Report of a foreign issuerDec 4, 2023Current reportSEC
6-K · Report of a foreign issuerDec 1, 2023Current reportSEC
6-K · Report of a foreign issuerNov 30, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerOct 18, 2023Current reportSEC
6-K · Report of a foreign issuerOct 16, 2023Current reportSEC
6-K · Report of a foreign issuerOct 13, 2023Current reportSEC
6-K · Report of a foreign issuerOct 11, 2023Current reportSEC
6-K · Report of a foreign issuerSep 26, 2023Current reportSEC
6-K · Report of a foreign issuerSep 8, 2023Current reportSEC
6-K · Report of a foreign issuerSep 6, 2023Current reportSEC
424B5 · ProspectusSep 1, 2023Offer documentSEC
6-K · Report of a foreign issuerSep 1, 2023Current reportSEC
6-K · Report of a foreign issuerAug 23, 2023Current reportSEC
6-K · Report of a foreign issuerAug 23, 2023Current reportSEC
6-K · Report of a foreign issuerAug 17, 2023Current reportSEC
6-K · Report of a foreign issuerAug 15, 2023Current reportSEC
6-K · Report of a foreign issuerJul 21, 2023Current reportSEC
20-F/A · Annual report, amendedJun 13, 2023Annual reportSEC
6-K · Report of a foreign issuerJun 13, 2023Current reportSEC
6-K · Report of a foreign issuerJun 5, 2023Current reportSEC
6-K · Report of a foreign issuerMay 25, 2023Current reportSEC
6-K · Report of a foreign issuerMay 23, 2023Current reportSEC
6-K · Report of a foreign issuerMay 17, 2023Current reportSEC
6-K · Report of a foreign issuerApr 27, 2023Current reportSEC
6-K · Report of a foreign issuerApr 26, 2023Current reportSEC
20-F · Annual reportApr 26, 2023Annual reportSEC
6-K · Report of a foreign issuerApr 24, 2023Current reportSEC
6-K · Report of a foreign issuerApr 20, 2023Current reportSEC
6-K · Report of a foreign issuerApr 18, 2023Current reportSEC
6-K · Report of a foreign issuerApr 13, 2023Current reportSEC
6-K · Report of a foreign issuerApr 10, 2023Current reportSEC
6-K · Report of a foreign issuerApr 4, 2023Current reportSEC
6-K · Report of a foreign issuerApr 4, 2023Current reportSEC
6-K · Report of a foreign issuerMar 31, 2023Current reportSEC
6-K · Report of a foreign issuerMar 28, 2023Current reportSEC
6-K · Report of a foreign issuerMar 22, 2023Current reportSEC
6-K · Report of a foreign issuerMar 21, 2023Current reportSEC
6-K · Report of a foreign issuerMar 20, 2023Current reportSEC
6-K · Report of a foreign issuerMar 17, 2023Current reportSEC
6-K · Report of a foreign issuerMar 17, 2023Current reportSEC
6-K · Report of a foreign issuerMar 15, 2023Current reportSEC
6-K · Report of a foreign issuerMar 8, 2023Current reportSEC
6-K · Report of a foreign issuerJan 5, 2023Current reportSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerJan 3, 2023Current reportSEC
6-K · Report of a foreign issuerDec 29, 2022Current reportSEC
6-K · Report of a foreign issuerDec 29, 2022Current reportSEC
6-K · Report of a foreign issuerDec 27, 2022Current reportSEC
6-K · Report of a foreign issuerDec 16, 2022Current reportSEC
6-K · Report of a foreign issuerDec 14, 2022Current reportSEC
6-K · Report of a foreign issuerDec 14, 2022Current reportSEC
6-K · Report of a foreign issuerDec 6, 2022Current reportSEC
6-K · Report of a foreign issuerNov 23, 2022Current reportSEC
6-K · Report of a foreign issuerNov 23, 2022Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC

This page holds 200 of 496 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tiziana Life Sciences Ltd’s releases · as of Jan 16, 2026

Common shares
127,259,131
Fully diluted
134,299,131

Fully diluted

LineSharesAs of
Common shares127,259,131
Warrants7,040,000Jan 16, 2026

Warrants and options

Lot
Warrants · US$1.50 · expiry not stated

Share count over time

CountShares
Nov 22, 2026127,259,131

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Marshall Wace, LLP1.18MUS$1.32MSep 30, 2026
Citadel616KUS$684KSep 30, 2026
Renaissance Technologies500KUS$555KSep 30, 2026
Mid-American Wealth Advisory Group, Inc.449KUS$498KSep 30, 2026
Dauntless Investment Group, LLC301KUS$334KSep 30, 2026
Goldman Sachs153KUS$169KSep 30, 2026
Zhang Financial LLC140KUS$156KSep 30, 2026
Jane Street121KUS$134KSep 30, 2026
Focus Partners Wealth79,365US$88,095Sep 30, 2026
HSBC62,437US$67,432Sep 30, 2026
All 36 holders
HolderSharesValueAs of
Morgan Stanley53,656US$59,559Sep 30, 2026
China Universal Asset Management Co., Ltd.50,000US$47,685Sep 30, 2026
Ewa, LLC42,435US$47,103Sep 30, 2026
XTX Topco Ltd41,593US$46,168Sep 30, 2026
Geode Capital35,968US$39,924Sep 30, 2026
Venture Visionary Partners LLC20,000US$22,200Sep 30, 2026
Rachor Investment Advisory Services, LLC17,000US$18,870Sep 30, 2026
Osaic Holdings, Inc.16,300US$15,485Sep 30, 2026
Susquehanna14,556US$16,157Sep 30, 2026
Two Sigma13,536US$15,025Sep 30, 2026
Corient Private Wealth LP12,179US$13,519Sep 30, 2026
JNBA Financial Advisors12,000US$13,320Sep 30, 2026
Captrust Financial Advisors11,000US$12,210Sep 30, 2026
LPL Financial LLC10,500US$11,655Sep 30, 2026
Private Advisor Group, LLC10,000US$11,100Sep 30, 2026
Wealth Alliance, LLC10,000US$11,100Sep 30, 2026
JPMorgan8,932US$8,518Sep 30, 2026
BFC Planning, Inc.8,000US$8,880Sep 30, 2026
UBS5,032US$5,586Sep 30, 2026
DiNuzzo Private Wealth, Inc.5,000US$5,550Sep 30, 2026
Jones Financial Companies Lllp1,651US$1,668Sep 30, 2026
Wells Fargo1,000US$1,110Sep 30, 2026
Tradewinds Capital Management, LLC258US$287Sep 30, 2026
IFP Advisors, Inc100US$111Sep 30, 2026
RBC2Sep 30, 2026
Caitong International Asset Management Co., Ltd1US$1Sep 30, 2026

Funds

HolderSharesValueAs of
Goldman Sachs Absolute Return Tracker Fund87,033US$111KJun 30, 2026
Fidelity Nasdaq Composite Index Fund78,204US$110KMay 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Elrifi Ivor
Officer: Chief Executive Officer
Buy237,616USD 1.00US$238KAug 5, 2026
Elrifi Ivor
Officer: Chief Executive Officer
Buy83,807USD 0.97US$81,293Aug 4, 2026
Elrifi Ivor
Officer: Chief Executive Officer
Buy667,000USD 1.00US$667KAug 3, 2026
Cerrone Gabriele M
Director, 10% owner
Buy42,357USD 0.99US$41,933Jul 21, 2026
Cerrone Gabriele M
Director, 10% owner
Buy15,000USD 1.11US$16,650Jun 12, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gabriele Cerrone
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); OKYO Pharma Limited (Non-Executive Chairman · Since at least Jul 21, 2026)
Executive Chairman · Since at least Jun 15, 2026
John Brancaccio
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); OKYO Pharma Limited (Director · Since at least Mar 18, 2026)
Non-Executive Director · Since at least Nov 5, 2026
Keeren Shah
Other companies: OKYO Pharma Limited (Chief Financial Officer · Since at least May 16, 2022); Accustem Sciences Inc (Chief Finance Officer · Since at least Dec 1, 2021)
Chief Operating Officer & Chief Financial Officer · Since at least Mar 18, 2026
Willy Simon
Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 4, 2026); OKYO Pharma Limited (Non-Executive Director · Since at least Nov 4, 2026)
Non-Executive Director · Since at least Nov 4, 2026
Paul Spencer
Other companies: OKYO Pharma Limited (Business Development and Investor Relations · Since at least Oct 6, 2026)
Business Development, and Investor Relations · Since at least Oct 21, 2026
Ivor ElrifiChief Executive Officer & Executive Director · Since at least Mar 18, 2026
Richard KimChief Medical Officer · Since at least Nov 5, 2026
William TenteChief Regulatory Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Tiziana Life Sciences Ltd.